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Abstract: A diffusely invasive nature is a major obstacle in treating a malignant brain tumor,
“diffuse glioma”, which prevents neurooncologists from surgically removing the tumor cells even in
combination with chemotherapy and radiation. Recently updated classification of diffuse gliomas
based on distinct genetic and epigenetic features has culminated in a multilayered diagnostic approach
to combine histologic phenotypes and molecular genotypes in an integrated diagnosis. However, it is
still a work in progress to decipher how the genetic aberrations contribute to the aggressive nature of
gliomas including their highly invasive capacity. Here we depict a set of recent discoveries involving
molecular genetic determinants of the infiltrating nature of glioma cells, especially focusing on
genetic mutations in receptor tyrosine kinase pathways and metabolic reprogramming downstream
of common cancer mutations. The specific biology of glioma cell invasion provides an opportunity to
explore the genotype-phenotype correlation in cancer and develop novel glioma-specific therapeutic
strategies for this devastating disease.
Keywords: glioma cell invasion; microenvironment; isocitrate dehydrogenase (IDH); mammalian
target of rapamycin complex 2 (mTORC2); metabolic reprogramming
1. Introduction—Invasion as a Key Feature in Gliomas
Recent advances in the identification of detailed genetic and epigenetic profiling in diffuse gliomas
have led to the refinement of glioma classification [1,2]. However, current therapeutics for diffuse
gliomas are still inadequate, and the patients eventually succumb to the disease despite the combination
of treatment options for diffuse glioma. One of the main reasons for this therapeutic failure could be
attributed to a key characteristic of glioma cells to vigorously infiltrate adjacent brain tissue, which is
responsible for the term “diffuse” glioma. The highly invasive capacity of diffuse glioma cells prevents
total resection of the tumor during surgery, and the investigation of the mechanism of glioma cell
invasion has thus received a great deal of interest in the field.
From a histopathological standpoint, infiltration of glioma cells has been a well-recognized
characteristic for the diagnostics of diffuse gliomas. For instance, glioma cells migrate along existing
brain structures including the brain parenchyma (especially around neuronal cells), blood vessels,
white matter tracts and subpial spaces, so-called “Scherer’s secondary structures”, reported by Hans
Joachim Scherer, a German neuropathologist in 1938 [3]. Careful observations of these histological
features of glioma invasiveness have revealed the important contribution of microenvironment in
the tumor to support glioma cell migration. Further, the recent molecular biological approaches have
unraveled the underlying mechanism of the infiltrating nature of glioma cells, which cleverly use the
intracellular systems originally residing in the migratory neural constituents in the brain. It would be
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thus important that future endeavor be directed to examine the connection between genetic/epigenetic
aberrations and biochemical functions including cellular invasion in glioma cells.
We herein review a set of recent discoveries involving the aggressive infiltrating nature of
glioma cells. A systematic search of PubMed for the literature analyses was performed between
1999 and 2017 with a combination of the keywords: “glioma”, “glioblastoma”, “invasion”, “migration”,
“molecular”, “genetic” and “metabolism”, and reference articles were also garnered through the
authors’ own file collections. We especially focus on intracellular molecular machineries to drive
migratory activity of glioma cells as well as their intricate interaction with the microenvironmental
components. We also discuss how the infiltrating nature could be promoted by genetic mutations in
receptor tyrosine kinase (RTK) pathways, which highlight the integration of genetic aberrations with
altered signaling, metabolic reprogramming, and epigenetic changes downstream of common cancer
mutations, potentially providing new therapeutic opportunities for these deadly types of brain tumors.
2. Molecular Underpinnings of Glioma Cell Invasion
2.1. Exploitation of Migratory Traits of Existent Neural Cells
A significant analogy has traditionally been recognized between glioma cell invasion and the
migration pattern of normal neural progenitor cells during development. To morphologically support
this notion, studies with time-lapse imaging of neural progenitor cells and glioma cells migrating
ex vivo in the brain slices demonstrated remarkable similarity in the morphology and dynamics of
migration patterns where the cells protrude a leading process before the nuclear translocation [4–6].
The observation suggests a role of microtubules and associated proteins in the migration of active
progenitor and glioma cells and raises their potentiality as markers for detecting infiltrating glioma
cells in the brain. Of note, DCX (doublecortin) and LIS1 (lissencephaly-1), the causative genes for
X-linked lissencephaly and type 1 lissencephaly respectively, are expressed in infiltrating glioma cells
(Figure 1), delineating the infiltrating glioma cells in the brain comparable to the expression pattern of
MAP-2e, a splicing variant of MAP-2 (microtubule-associated protein-2) that has been shown to detect
glioma invasion into the adjacent brain tissue [7–9]. Disruption of these gene products significantly
retards the migration of glioma cells (Figure 1). The findings are compatible with the assumption that
these developmental genes could play a role in tumor cell invasion, analogous to their roles in neural
progenitors during brain development [10].
Actin–myosin molecular motors provide the main contractile force in intrinsic neural cells, and thus
contribute to the support of cell migration. Previous studies demonstrated that invasive glioma cells use
non-muscle myosin II to generate the contractile forces to squeeze their cell bodies through the small intercellular
spaces that characterize brain white matter and cortex, promoting the migration of glioma cells [11–13]. Cellular
migration with this system is thus responsive to environmental stiffness within tumor tissue to achieve
maximal migration capability [14,15] with an additional support of ion and water channels [3,16]. Additionally,
microtubule-associated motor proteins including kinesin and dynein, which play essential roles in intracellular
transport and in the formation of the mitotic spindle apparatus, are also reported to be involved in the infiltrative
capacity of glioma cells and could be the therapeutic and diagnostic targets [9,17].
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Figure 1. Neuro-developmental gene products in infiltrating glioma cells. (A,B) Microtubule-
associated proteins, which are important in migration of glial ((A) MAP-2e) and neural ((B) DCX) 
progenitor cells clearly delineate infiltrating glioma cells, well demonstrating the leading processes. 
Images reproduced from [7]. Scale bar = 15 µm; (C,D) GFP-labeled C6 rat glioma cell lines vigorously 
migrate out of the sphere ((C) 40.2%) whereas overexpression of dominant negative form of neuro-
developmental gene LIS1 (d-LIS1) significantly reduced the ratio of migration ((D) 9.3%), suggesting 
its role in glioma cell invasion. MAP-2e, microtubule-associated protein-2e; DCX, doublecortin; EGFP, 
enhanced green fluorescent protein; d-LIS1, dominant negative form of lissencephaly-1. 
2.2. Interaction with Tumor Microenvironment 
Tumor cells do not solely rely on their own migratory machineries, but on the interaction with 
surrounding microenvironment to support their invasive capacity. Various components exist within 
or around the tumor including blood vessels, neuropils consisting of dendrites and glial processes, 
and the white matter axonal tracts. Glioma cells display vigorous avidity for the extracellular matrix 
(ECM) constituting these microenvironmental components, and the close interaction with ECM 
components is inevitable for the efficient migration of glioma cells in the brain. As aforementioned, 
the protrusion of a leading process precedes the nuclear translocation in cellular migration, which is 
an integrated process with a cascade of projection of the leading edge from a migrating cell, anchoring 
to the ECM, and detachment of the trailing end [18]. Cell attachment is mediated by cell–cell and cell–
matrix receptors, such as integrins, cadherins and cell adhesion molecules (CAMs) [19]. Integrins are 
transmembrane receptors involved in cell–cell and cell–matrix interactions, and glioma cells display 
several integrin family members with β1 integrin playing a central role in glioma invasion [20], by 
activating tyrosine kinases such as focal adhesion kinase (FAK) [21]. Cell detachment requires the 
activity of proteases that degrade ECM components, such as matrix metalloproteinases (MMPs). 
Glioma cells secrete an array of proteases to be involved in glioma cell invasion, including MMP2 
and MMP9 [22,23], and the membrane-bound MMP, MT1-MMP (also known as MMP-14) [24]. The 
intricate interaction between glioma cells and ECM with the cellular receptors and proteases enables 
tumor cells to remodel the microenvironment to favor tumor cell invasion. 
Microglia/macrophage is one of the immune cells in the brain that has been reported to constitute 
a significant subpopulation in the microenvironment of malignant tumors. These tumor-infiltrating 
microglia/macrophages are collectively referred to “tumor-associated macrophages” (TAMs). TAMs 
could be recruited in the tumor from resident brain microglia and monocyte-derived macrophages 
from the circulation, and glioblastoma (GBM), the most malignant astrocytic tumor, is often heavily 
infiltrated by such cells of myeloid origin [25]. TAMs have been implicated in several roles in GBM 
progression including proliferation, survival, immunosuppression and motility [26,27]. Various 
studies have sought to determine the role of TAMs in migration and invasion of glioma cells. It was 
reported that microglia can secrete a soluble motogenic factor that acts on glioma cells and 
substantially enhance the migration of tumor cells [28]. Further, microglia and glioma cells cooperate 
in the tumor tissue to secrete and activate MMPs, which mediate the breakdown of ECM required for 
invasion of the tumor [29]. 
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2.2. Interaction with Tumor Microenvironment
Tumor cells do not solely rely on their own migratory machineries, but on the interaction with
surrounding microenvironment to support their invasive capacity. Various components exist within
or around the tumor including blood vessels, neuropils consisting of dendrites and glial processes,
and the white matter axonal tracts. Glioma cells display vigorous avidity for the extracellular matrix
(ECM) constituting these microenvironmental components, and the close interaction with ECM
comp nents is inevitable for the efficient migration of glioma cells in the brain. As aforementioned,
the protrusion of a leading process precedes the nuc ear translocation in cellular migratio , which is
an integrated process with a cascade of projection of the leading edge from a migrating cell, anchoring
to the ECM, and detachment of the trailing end [18]. Cell attachment is mediated by cell–cell and
cell–matrix receptors, such as integrins, cadherins and cell adhesion molecules (CAMs) [19]. Integrins
are transmembrane receptors involved in cell–cell and cell–matrix interactions, and glioma cells
display several integrin family members with β1 integrin playing a central role in glioma invasion [20],
by activating tyrosine kinases such as focal adhesion kinase (FAK) [21]. Cell detachment requires
the activity of pr t ases that deg ade ECM components, such as matrix metalloproteinases (MMPs).
Glioma cells secrete an array of proteases to be invo ved in glioma cell invasion, including MMP2 and
MMP9 [22,23], and the membrane-bound MMP, MT1-MMP (also known as MMP-14) [24]. The intricate
interaction between glioma cells and ECM with the cellular receptors and proteases enables tumor
cells to remodel the microenvironment to favor tumor cell invasion.
Microglia/macrophage is one of the immune cells in the brain that has been reported to constitute
a significant subpopulation in the microenvironment of malignant tumors. These tumor-infiltrating
microglia/macrophages are collectively referred to “tumor-associated macrophages” (TAMs). TAMs could
be recruited in the tum r from re ident brain microglia a d monocyte-derived macrophages from the
circulation, and glioblastoma (GBM), the st malignant ast ocytic tumor, is ften heavily infiltrated
by such cells of myeloid origin [25]. TAMs have been implicated in several roles in GBM progression
including proliferation, survival, immunosuppression and motility [26,27]. Various studies have sought
to determine the role of TAMs in migration and invasion of glioma cells. It was reported that microglia
can secrete a soluble motogenic factor that acts on glioma cells and substantially enhance the migration of
tumor cells [28]. Further, microglia and glioma cells cooperate in the tumor tissue to secrete and activate
MMPs, which mediate the breakdown of ECM required for invasion of the tumor [29].
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3. Cardinal Regulators of Glioma Invasiveness—Genetic and Metabolic Aberrations Drive
Glioma Cell Invasion
3.1. Invasive Phenotypes in IDH-Mutant Gliomas
One of the epoch-making discoveries in glioma pathogenesis is the identification of hotspot
mutations in isocitrate dehydrogenase 1 (IDH1), or less commonly IDH2 genes in more than
70% of diffusely infiltrating World Health Organization (WHO) grade II and grade III astrocytic
and oligodendroglial gliomas, as well as in a minor fraction of GBMs that develop from lower
grade gliomas (LGGs) [2,30,31]. As a normal function, the IDH enzymes catalyze the oxidative
carboxylation of isocitrate to α-ketoglutarate (α-KG) in combination with the reduction of nicotinamide
adenine dinucleotide phosphate (NADP+) to NADPH. On the other hand, mutant IDH obtains a
neomorphic activity that converts a-KG to D-2-hydroxyglutarate (D-2-HG) in an NADPH-consuming
reduction, which competitively inhibits a-KG-dependent dioxygenases, eventually shifting the
genome-wide histone and DNA methylome in gliomas [32,33]. These epigenetic changes are considered
to lock tumor cells in an immature state [34], but the association of IDH mutations and invasive
phenotypes remain to be clarified. Although GBM with a mutant IDH gene (GBM, IDH-mutant)
have a better prognosis than high grade gliomas with wildtype IDH [35], the strong correlation
between IDH1 mutational status and the invasive characteristics was observed based on MRI
(magnetic resonance imaging) studies [36]. Interestingly, the neurotransmitter glutamate in the brain
may act as a chemotactic compound, specifically for IDH-mutated glioma cells [37]. In addition,
overexpression of mutant IDH2 (R172G) in glioma cells induces nuclear accumulation of β-catenin
and upregulation of HIF-1α (hypoxia-inducible factor-1α) signaling that were closely related with
tumor invasion and chemoresistance [38]. Alternatively, IDH mutations promote gliomagenesis by
disrupting chromosomal topology and allowing aberrant regulatory interactions that induce oncogene
expression such as PDGFR (platelet-derived growth factor receptor) [39], the combination of which is
frequently observed in the proneural subtype of GBM [40,41]. Of note, PDGF signaling significantly
promotes migratory capacity of glioma cells [42,43]. Tumor cells demonstrate highly invasive features
in PDGF-induced glioma models, and PDGF-induced tumor cells transform surrounding NG2
proteoglycan-positive glial progenitors into migratory morphology in a paracrine fashion (Figure 2).
Further, a number of Iba-1-positive microglia are observed in the invasive front of PDGF-induced
gliomas, and microglial cells could also transform NG2-positive glial progenitors into migratory
morphology (Figure 2). The action of PDGF signaling thus may alternatively explain the invasive
phenotypes of IDH-mutant glioma cells. Future studies would be necessary to further clarify the
association between IDH mutation, epigenetic changes (G-CIMP: glioma-CpG island methylator
phenotype) [33], and glioma cell invasion.
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Figure 2. RTK signaling as a key determinant of glioma cell invasion. (A) In PDGF (platelet-derived 
growth factor)-induced rat glioma models, tumor cells demonstrate highly invasive features, so-called 
“Scherer’s secondary structures.” Scale bar = 50 µm; (B) Co-culture of PDGF-induced tumor cells (red) 
and NG2-positive glial progenitors (green) transforms glial progenitors into migratory morphology 
in a paracrine fashion; (C) In PDGF-induced rat glioma models, significant number of Iba-1-positive 
microglia are observed in the invasive front of the tumor. Scale bar = 15 µm; (D) Co-culture of 
microglial cell lines (green) and NG2-positive glial progenitors (red) from the rat brain transforms 
glial progenitors into migratory morphology, suggesting pro-invasive role of microglia. Note that the 
mature glial progenitor cells display oligodendroglial morphology with multipolar branches 
(arrowhead). GFP, green fluorescent protein; DsRed, Discosoma species red fluorescent protein; 
PDGF, platelet-derived growth factor; Iba-1, ionized calcium binding adapter molecule 1. 
3.2. Invasive Phenotypes in IDH-Wildtype Gliomas 
Recent progresses in multi-disciplinary molecular analyses of cancers, based on large-scale DNA 
methylation profiling and next-generation sequencing approaches, have led to the molecular 
stratification of GBM by the combination of molecular genetic signatures. The Cancer Genome Atlas 
(TCGA) Research Network has generated the comprehensive catalog of genomic abnormalities 
driving tumorigenesis and has clarified three core pathways in GBM: (1) RTK/RAS/PI3K signaling, 
(2) p53 and (3) Rb pathways [44,45]. Among these, the genomic characterization of GBM with a 
wildtype IDH gene (GBM, IDH-wildtype) reveals frequent genetic alterations of the growth factor 
receptor-PI3K-Akt signaling pathway that activate mammalian target of rapamycin (mTOR) 
signaling [45]. Interestingly, RTK-PI3K/Akt-mTOR pathways are well known to promote invasive 
phenotypes of the glioma cells (Figure 2). 
Epidermal growth factor receptor (EGFR, located on chromosome 7p12) amplification is a 
hallmark of GBM, specifically primary tumors [46,47]. About 50% of EGFR-amplified GBM express a 
ligand-independent truncated mutant variant, EGFRvIII, which is characterized by genomic deletion 
of exons 2–7, resulting in a constitutively active oncogenic form [47]. The presence of EGFR mutations 
significantly promotes the invasive capacity of glioma cells through the regulation of integrin [48,49], 
CAMs [50], urokinase-type plasminogen activator/receptor (uPA/uPAR) [51,52], MMPs [53,54] and 
microRNAs [55,56]. Wild-type EGFR is reported to be involved in the switch between invasive and 
angiogenic phenotypes in GBM [57]. EGFR pathway may also be associated with epithelial-
mesenchymal transition (EMT) in gliomas [58], which plays a key role in cancer invasion and 
metastasis [59]. Located downstream of EGFR signaling, we have revealed the important role of 
mTOR complex 2 (mTORC2) in glioma pathogenesis through chemoresistance and metabolic 
reprogramming [60,61]. Of note, mTORC2 may be involved in the invasive phenotype of cancer cells 
[62–64] since mTORC2 functions upstream of Rho GTPases to organize the actin cytoskeleton [65,66]. 
Further studies are needed to elucidate the involvement of mTORC2 in the invasiveness of glioma 
cells with an activation of the EGFR-PI3K/Akt-mTOR pathway. 
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with epithelial-mesenchymal transition (EMT) in gliomas [58], which plays a key role in cancer
invasion and metastasis [59]. Located downstream of EGFR signaling, we have revealed the
important role of mTOR complex 2 (mTORC2) in glioma pathogenesis through chemoresistance
and metabolic reprogramming [60,61]. Of note, mTORC2 may be involved in the invasive phenotype
of cancer cells [62–64] since mTORC2 functions upstream of Rho GTPases t organize the actin
cytoskeleton [65,66]. F rther st dies are needed to elucidate the involvement of mTORC2 in the
invasiveness of glioma cells with an activatio f the EGFR-PI3K/Akt-mTOR pathway.
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3.3. Metabolic Reprogramming as a Driving Force of Glioma Cell Invasion
Metabolic reprogramming or “the Warburg effect” is re-emerging as a central hallmark of
cancer [67]. Cancer cells demonstrate a unique metabolism to convert the majority of glucose into
lactate even in the presence of sufficient oxygen. Of interest, emerging evidences support the role of
metabolic reprogramming in cancer invasive phenotypes. For instance, metabolic reprogramming
supports the invasive phenotype in malignant melanoma [68], and metabolic stress regulates
cytoskeletal dynamics and metastasis of cancer cells [69]. Importantly, major genetic and signaling
aberrations in IDH-wildtype GBM including mTORC2 (in the EGFR-mTOR pathway) and TERT
(telomerase reverse transcriptase) play an important role in transcriptional regulation and metabolic
reprogramming [70,71], possibly linking genetic mutations and invasive phenotypes through metabolic
reprogramming (Figure 3).
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mTORC2, mammalian target of rapamycin complex 2; mIDH, mutant form of IDH enzymes; α-KG, α-
ketoglutarate; 2-HG, 2-hydroxyglutarate; TERT, telomerase reverse transcriptase; mut, mutation; CAM, 
cell adhesion molecule; MMP, matrix metalloproteinase; uPA, urokinase receptor. 
Metabolic reprogramming results in changes in intracellular nutrient levels, which can affect 
oncogenic signaling via control of epigenetics as well as post-translational modifications of 
cytoplasmic proteins [72–74]. The findings suggest the involvement of intermediary metabolites in 
the important cellular functions in cancer cells including cell migration. Glycolytic metabolites, such 
as glucose-6-phosphatase, are key metabolic regulators of GBM invasion [75]. NAD(H), a product in 
glycolysis and TCA cycle, regulates cell motility coupled with pyruvate-lactate conversion by lactate 
dehydrogenase (LDH) and with changes in intracellular and extracellular pH [76]. Of note, recent 
studies demonstrated the involvement of NAD+ metabolism in IDH1 mutant cancers [77], suggesting 
the role of metabolic reprogramming in cancer cell invasion even in IDH-mutant gliomas. 
Glutaminolysis is an essential anaplerotic part of the cancer metabolism, and glutamate is produced 
by the tumor from glutamine and released through the cystine-glutamate antiporter xCT, which is 
recently reported to be regulated by mTORC2 [78]. Glioma cells utilize glutamate to promote invasion 
by inducing oscillatory intracellular Ca2+ changes through activation of Ca2+-permeable AMPA 
receptors [3,79]. 
Figure 3. Metabolic reprogramming as a driving force of glioma invasive phenotype. Mutations in IDH
that are identified as an early enetic event i grade II/III LGG and second ry GBM, a genetic alteratio s
of key components of the growth factor receptor-PI3K-Akt-mTOR, which are main genetic aberrations in de
novo GBM, play an essential role in metabolic reprogramming in diffuse gliomas. Metabolic reprogramming
by mTORC2 (also possibly by TERT) could contribute to invasive phenotypes of glioma cells, in combination
with pro-invasive molecules produced by EGFR signaling pathways. Biochemical microenvironment such
as necrosis (hypoxia) also significantly affects the migratory capacity of the glioma cells. IDH, isocitrate
dehydrogenase; LGG, lower grade glioma; GBM, glioblastoma; RTK, receptor tyrosine ki ase; EGFRvIII,
epidermal growth factor receptor variant III; mTORC2, mammalian target of rapamycin complex 2;
mIDH, mutant form of IDH enzymes; α-KG, α-ketoglutarate; 2-HG, 2-hydroxyglutarate; TERT, telomerase
reverse transcriptase; mut, mutation; CAM, cell adhesion molecule; MMP, matrix metalloproteinase;
uPA, urokinase receptor.
Metabolic reprogramming results in changes in intracellular nutrient levels, which can affect
oncogenic signaling via control of epigenetics as well as post-translational modifications of
cyt plasmic proteins [72–74]. The findings su gest the involvement of int rmediary metabolites
in the important cellular functions in cancer cells including cell migration. Glycolytic metabolites,
such as glucose-6-phosphatase, are key metabolic regulators of GBM invasion [75]. NAD(H), a product
in glycolysis and TCA cycle, regulates cell motility coupled with pyruvate-lactate conversion by
lactate dehydrogenase (LDH) and with changes in intracellular and extracellular pH [76]. Of note,
recent studies demonstrated the involvement of NAD+ metabolism in IDH1 mutant cancers [77],
suggesting the role of metabolic reprogramming in cancer cell invasion even in IDH-mutant gliomas.
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Glutaminolysis is an essential anaplerotic part of the cancer metabolism, and glutamate is produced
by the tumor from glutamine and released through the cystine-glutamate antiporter xCT, which is
recently reported to be regulated by mTORC2 [78]. Glioma cells utilize glutamate to promote invasion
by inducing oscillatory intracellular Ca2+ changes through activation of Ca2+-permeable AMPA
receptors [3,79].
From a morphological standpoint, “microvascular proliferation” and “palisading necrosis” are
diagnostic hallmarks of GBM, which could also establish specific metabolic microenvironment/niche
for glioma cells. In human GBM surgical specimens, tumor cells palisading around necrotic areas are
exposed to hypoxic stimuli and induce dramatic upregulation of HIF-1α. Interestingly, GBM cells
around necrosis often display migratory morphology, which may implicate hypoxia-regulated
migration toward or away from the necrotic regions [80,81], and limitations in oxygen diffusion
would be further affected by abnormal tumor vasculatures. Experimental models support the idea
that tumor hypoxia results in increased GBM cell migration, and GBM cells respond to hypoxia with
an induction of c-Met, which is the receptor for hepatocyte growth factor to secrete uPA and MMPs for
avidly degrading ECM and invading the surrounding tissue [81].
4. Conclusions and Outlook
The traditional histological classification of diffuse gliomas has been replaced by the
genetics-oriented classification system based on recent identification of distinct genetic and epigenetic
features. Through the efforts to clarify the link between genetic aberrations and glioma biology,
“the genotype-phenotype correlation” will be unveiled for further refinement of glioma classification.
One of the key mechanisms to link the genetic aberrations with glioma pathogenesis is through cancer
metabolic reprogramming. Genetic aberrations render glioma cells to increase glucose uptake to
meet the increased energetic and biosynthetic demands imposed by rapid tumor growth, modulate
epigenetic landscapes and eventually drive tumor progression [82]. Interestingly, cell proliferation
and migration seem to be a dichotomic phenomenon, and glioma cells may utilize metabolic
reprogramming for proliferation in the center of the tumor tissue and for infiltration in the periphery,
both of which are a key characteristic of diffuse glioma.
The propensity of glioma cells to move and invade the brain tissue is considered to be a
malignant feature, but these biological traits may be inherited from their neural ancestors or residing
cells. Therefore, caution should be made in treatment when trying to exploit the invasive nature
of glioma cells. Therapeutic targets should not be the migratory system itself shared by cancer
and inherent cells, but the upstream genetic, epigenetic and metabolic aberrations to regulate
invasive phenotypes specific to cancer cells. Additionally, therapeutic strategies should take into
consideration not only the intracellular reprogramming of metabolism in cancer cells, but the
biochemical environment that can affect the infiltrative behavior of tumor cells in a genotype-specific
fashion, potentially by shifting the relative fitness of cells bearing a mutation to grow and invade within
that metabolic niche. Future studies are needed to determine precisely how chief genetic mutations
and subsequent epigenetic changes in diffuse glioma facilitate invasive phenotype through cancer
metabolic reprogramming in combination with extracellular environment, in order to orchestrate these
insights into more effective treatments for glioma patients.
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